Posted by AGORACOM-JC
at 7:47 AM on Thursday, January 28th, 2021
Three-year $150,000 SDK licensing and revenue sharing agreement executed.
Announced the execution of a three-year $150,000 SDK licensing plus revenue sharing agreement to deliver Augmented Reality (“AR”) immersive experiences integrated with the new IMP Event App ( www.touchaprize.com ).
In 2019, IMP successfully delivered an AR Scavenger Hunt for the Greater Milwaukee Auto Show presented by Adamm. IMP recent Auto Show clients include: Greater Milwaukee , Alabama , St. Louis , Hawaii International, Sacramento , Orlando , Tampa and other Motor Trend shows.
VANCOUVER, BC and ERIE, Pa, Jan. 28, 2021 –Imagine AR Inc. (CSE:IP) (OTCQB: IPNFF) (“ImagineAR”) and Interactive Marketing Promotions (“IMP) , are excited to announce the execution of a three-year $150,000 SDK licensing plus revenue sharing agreement to deliver Augmented Reality (“AR”) immersive experiences integrated with the new IMP Event App ( www.touchaprize.com ). In 2019, IMP successfully delivered an AR Scavenger Hunt for the Greater Milwaukee Auto Show presented by Adamm. IMP recent Auto Show clients include: Greater Milwaukee , Alabama , St. Louis , Hawaii International, Sacramento , Orlando , Tampa and other Motor Trend shows.
Using ImagineAR’s licensed AR SDK and cloud-based studio suite, IMP will be delivering immersive AR engagements for manufacturers to consumers attending online virtual and near future in-person automobile shows throughout North America. In addition to on-site and virtual AR Scavenger Hunts, AR will be used to place leading product experts from automobile manufacturers virtually ‘on location’ with the consumer to provide new model information as either an avatar or hologram.
“ImagineAR continues to be the global leader in delivering dynamic mobile augmented reality engagements. By integrating the ImagineAR platform with our IMP app, we are providing automobile shows the most advanced interactive consumer attendee engagement solution and data capture tool,” said Bob Kames, CEO IMP .
Posted by AGORACOM-JC
at 7:55 AM on Monday, January 25th, 2021
Received notice of a positive recommendation by Quebec’s Institut national d’excellence en santé et en services sociaux (“INESSS”) to the Health Minister for the inclusion of its Low Molecular Weight Heparin biosimilar (LMWH), Redesca ™ and Redesca ™ HP, on the list of medications covered by the Régie de l’assurance maladie du Québec (RAMQ) for the prevention and treatment of thromboembolic disorders.
“We are very pleased to have received a positive recommendation by INESSS, a key milestone in the coming commercial launch of Redesca™”, said Steve Saviuk , Valeo’s CEO.
MONTREAL , Jan. 25, 2021 – Valeo Pharma Inc . (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) (” Valeo ” or the ” Company “), a Canadian pharmaceutical company, announced today that it has received notice of a positive recommendation by Quebec’s Institut national d’excellence en santé et en services sociaux (“INESSS”) to the Health Minister for the inclusion of its Low Molecular Weight Heparin biosimilar (LMWH), Redesca ™ and Redesca ™ HP, on the list of medications covered by the Régie de l’assurance maladie du Québec (RAMQ) for the prevention and treatment of thromboembolic disorders.
“We are very pleased to have received a positive recommendation by INESSS, a key milestone in the coming commercial launch of Redesca™”, said Steve Saviuk , Valeo’s CEO. “Redesca™ has a long and strong history of safety and efficacy with more than 8 years of proven in-market data internationally. Redesca™ will be available across Canada and Valeo intends to pursue discussions for the inclusion of Redesca on all other provincial formularies. Valeo is planning to launch Redesca™ during the first half of 2021.”
In addition to being used primarily for treating and preventing deep vein thrombosis and pulmonary embolism, LMWHs are also now increasingly used as a first line of defense tool in the fight against Covid-19. The World Health Organization (“WHO”) issued guidance regarding the prophylaxis use of LMWH to help prevent complications in the clinical management of severe acute respiratory infections when novel coronavirus (COVID-19) infection is suspected.
Posted by AGORACOM-JC
at 7:49 AM on Monday, January 25th, 2021
Announced a partnership agreement with BOOK YOUR STADIUM ( www.bookyourstadium.com ) to deliver ‘one-of-a-kind’ AR experiences from historical soccer clubs in LaLiga ( Spain ) to fans around the world.
The clubs which BOOK YOUR STADIUM is currently offering in the platform are REAL MADRIDCF , REAL SOCIEDAD CF , REAL VALLADOLID CF, VALENCIA CF, ATHLETIC CLUB , CA OSASUNA , REAL BETIS BALOMPIÉ, and RC CELTA .
Throughout 2021, several national and international clubs are expected to join the platform.
VANCOUVER, BC and ERIE, Pa. , Jan. 25, 2020 – ImagineAR (IP:CSE) (IPNFF:OTCQB) an Augmented Reality company that enables sports teams, entertainers, brands and businesses to instantly create immersive global mobile phone AR campaigns, is excited to announce a partnership agreement with BOOK YOUR STADIUM ( www.bookyourstadium.com ) to deliver ‘one-of-a-kind’ AR experiences from historical soccer clubs in LaLiga ( Spain ) to fans around the world. The clubs which BOOK YOUR STADIUM is currently offering in the platform are REAL MADRIDCF , REAL SOCIEDAD CF , REAL VALLADOLID CF, VALENCIA CF, ATHLETIC CLUB , CA OSASUNA , REAL BETIS BALOMPIÉ, and RC CELTA . Throughout 2021, several national and international clubs are expected to join the platform.
Joaquín Martínez, CEO of BOOK YOUR STADIUM , states: ” We have developed a revolutionary online e-commerce fan engagement site and incorporated ‘best of breed’ innovative digital products. ImagineAR is a leader for sports fan AR engagement and we are going to partner on unique fan AR immersive experiences featuring top LaLiga soccer club players. Additionally, we are now an authorized ImagineAR partner to market their SDK platform to LaLiga clubs for integration into their existing mobile apps which are used by tens of millions of fans around the world.”
BOOK YOUR STADIUM ( www.bookyourstadium.com ), currently available in Spanish, is expected to be available in English in February 2021 and expand globally. Initially, soccer fans can choose from over 200 experiences, adapted to the current health restrictions, to select from historical clubs in LaLiga. Some examples of experiences available include: access to virtual match experiences with exclusive content and games, e-sports matches with football players, Immersive AR experiences, virtual autographs, original match day events, or enjoy club lunch at home. In addition, there is the option of the SPORTBOX® , a themed gift box full of surprises with selected experiences from some clubs.
Posted by AGORACOM-JC
at 5:57 PM on Tuesday, January 19th, 2021
Valeo Pharma is already a successful, revenue generating, small cap Canadian pharmaceutical company that acquires the Canadian rights to commercialized drugs in other parts of the world that don’t have Canada on their radar as a target market.
This “in-license” business model is ingenious because it means ZERO developmental or clinical risk, which is the downfall of most small cap pharma companies.
This model has resulted in the following success:
$5.3M in revenues in the first 9 months of 2020 (ending July 31, 2020)
9 products currently in the market with an annual estimated peak sales of $40M/year
7 products in the pipeline with an annual estimated peak sales of $45M/year
In fact, capital markets confidence is so high that Valeo secured $8.6M in financing in the last half of the year with:
$6.9M Bought Deal financing at $1.20/shares
A $1.7M Oversubscribed debenture (non-convertible)
If that was all Valeo had, most investors would be happy to sit back and watch the Company grow.
But then came Redesca. We are going to save you the science and tell you that Redesca belongs to a class of anticoagulant medications (blood thinners) called LMWH. The size of the Canadian LMWH market is over $200M per year and Valeo believes they can capture 15-30% of this market. If you’re doing back of napkin math, that equates to $30,000,000 – $60,000,000 per year in revenues.
But how does a new product capture that much market share? Glad you asked because we asked CEO Steve Saviuk the same question. Competition is tough in all markets and they don’t let someone take 15-30% market share without one hell of a fight.
Saviuk agreed and gave the following reasons:
1. Redesca has an 8-year international track record of safety and efficacy. It is already well known
2. Redesca is flat out cheaper, which is music to the ears of Provincial Health Ministries whose budgets have been stretched to the max this year no thanks to COVID-19.
Vaelo is so confident that it stated “This is great news for the Canadian healthcare system …. and is expected to help provide significant savings to provincial healthcare systems.”
Well there you have it. Valeo is a great story. Watch the video.
HOLD ON. THERE’S MORE … A LOT MORE
In a recently issued newsletter by MDBriefCase entitled “Exploring Novel Therapeutic Approaches for Covid-19: Hesperidin vs Vitamin C” the newsletter stated that recently accumulated evidence suggests that Hesperidin supplementation may be useful as a prophylactic agent against SARS-Cov-2 infection and as a complementary treatment during COVID-19 disease. What does this mean?
Growing body of research suggests Hesperidin may interfere with SARS-CoV-2 infection process
Hesperidin may help against Covid-19 viral replication
Hesperidin is a potent antioxidant with anti-inflammatory activity that may help in controlling cytokine storm (where the body starts to attack its own cells and tissue rather than just the virus)
Valeo’s unique Hesperidin formulation (HESPERCO) is the only format available where every capsule contains 500mg of concentrated Hesperidin.
Now you have it. That’s the Valeo story as it applies to just 2 of their amazing products. There is a whole lot more to the story given their pipeline of products but we couldn’t cover it all in this great interview with CEO Steve Saviuk.
If you love revenue generating, growing and blue sky potential small cap companies, then this Valeo interview is a must watch.
Posted by AGORACOM-JC
at 7:14 AM on Monday, January 18th, 2021
Frederic Fasano named President and COO
Steve Saviuk continues as CEO and becomes Vice-Chairman of the Board of Directors
MONTREAL , Jan. 18, 2021 – Valeo Pharma Inc . (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) (” Valeo ” or the ” Company “), a Canadian pharmaceutical company, announced today the appointment of Mr. Frederic Fasano to the newly created position of President and Chief Operating Officer, effective January 18th , to augment its senior leadership team and support expansion of Valeo’s commercial activities. Mr. Fasano has also been elected to the Company’s Board of Directors effective as of today.
“It gives me true pleasure to welcome Frederic to the Valeo executive team in this important new role. He possesses extensive International pharmaceutical experience and his management skills are well suited to helping us build a leading innovative pharmaceutical company with a deep commitment to our selected therapeutic areas of focus”, said Steve Saviuk, CEO. “This increase in management depth, coupled with our solid foundation of products and people, positions us well for the dynamic growth we foresee in the coming years.”
Posted by AGORACOM-JC
at 12:14 PM on Thursday, January 14th, 2021
Commercial launch to impact first half 2021 revenue
$30 million forecasted annual peak sales
8 years of proven in-market safety Internationally
Low molecular weight heparin increasingly used to prevent COVID-19 driven complications
“The regulatory approval of Redesca is a significant corporate milestone for Valeo and also great news for the Canadian healthcare system. Mandatory use of biosimilars is increasingly being adopted across the country and is expected to help provide significant savings to provincial healthcare plans”, said Steve Saviuk , President and CEO. “With more than 8 years of proven in-market safety internationally and a robust supply chain ensuring product availability, we expect Redesca to play a major role in the achievement of our growth objectives”.
Posted by AGORACOM-JC
at 8:18 AM on Tuesday, January 12th, 2021
Announced the execution of a three-year $150,000 SDK licensing agreement to launch Augmented Reality immersive experiences integrated with Liquid Avatar ( www.liquidavatar.com ).
Liquid Avatar empowers user to manage, control and gain value from their biometrically verified Self Sovereign Identity and personal data ownership.
Using ImagineAR’s licensed AR SDK and cloud-based studio suite, KABN will deliver a series of dynamic AR interactions to Liquid Avatar mobile app users starting in early 2021.
TORONTO , VANCOUVER, BC and ERIE, Pa., Jan. 12, 2021 – Imagine AR Inc. (CSE: IP) (OTCQB: IPNFF) (” ImagineAR “) and KABN Systems NA Holdings Corp. ( CSE:KABN / OTC:TRWRF / FRA:4T51 ) (the ” Company “, ” KABN North America ” or ” KABN NA “), are excited to announce the execution of a three-year $150,000 SDK licensing agreement to launch Augmented Reality (“AR”) immersive experiences integrated with Liquid Avatar ( www.liquidavatar.com ). Liquid Avatar empowers user to manage, control and gain value from their biometrically verified Self Sovereign Identity and personal data ownership.
Using ImagineAR’s licensed AR SDK and cloud-based studio suite, KABN will deliver a series of dynamic AR interactions to Liquid Avatar mobile app users starting in early 2021. Liquid Avatar users will experience immersive consumer AR-based social, event, educational and information-based messages. Commercial enterprises and media companies will present dynamic measurable interactive AR offers to Liquid Avatar users knowing the consumer is real and verified thereby significantly reducing marketing waste and breakage. The range of opportunities are potentially limitless as Liquid Avatar’s Self Sovereign Identity platform is addressable to up to 100% of all online users.
Liquid Avatar users will soon be able to create and share interactive 3D greetings and messages that are automatically integrated with their Liquid Avatar icons and can be experienced inside the Liquid Avatar app. Liquid Avatar users will also be able to share AR enabled resumes, invitations, event programs, and other information with their social connections. Additionally, Liquid Avatar is exploring interactive digital wallets, which will allow users to easily visualize all their in-wallet verifiable access and identity credentials, like those for healthcare, gaming, travel, financial services, education, ecommerce, and government services.
“Augmented Reality provides a new way to see the world around us and allows KABN to empower Liquid Avatar’s known and verified users to take advantage of this interactive technology to engage with friends, family, and other connections,” said David Lucatch , CEO KABN . “ImagineAR’s platform provides immersive experiences and an effective way for us to instantly deliver AR opportunities to our constituents, therefore creating revenue and value opportunities for our expanding user base.”
According to the newsletter, Hesperidin has recently attracted the attention of researchers, because it binds to key proteins of SARS-CoV-2 1 . This may interfere with viral entry into host cells 4 .
In Wu et. al (2020 ), the screening of 1066 natural substances with potential antiviral effect, plus 78 antiviral drugs already known in the literature for their binding to SARS-CoV-2 proteins, Hesperidin was the only compound that could target the binding interface between viral Spike proteins and ACE-2 human receptors 2 .
Hesperidin can also bind to 3CLpro – the main protease responsible for the cleavage of SARS-CoV-2 peptides into functional units for virus replication and packaging within the host cells 1,3 . By doing so, it may help against COVID-19 viral replication 4 .
